首页> 美国卫生研究院文献>other >Quantitative Determination of a Potent Geranylgeranyl Diphosphate Synthase Inhibitor using LC- MS/MS: Derivatization and Application
【2h】

Quantitative Determination of a Potent Geranylgeranyl Diphosphate Synthase Inhibitor using LC- MS/MS: Derivatization and Application

机译:使用LC-MS / MS定量测定强效香叶基香叶酸二磷酸合酶抑制剂的衍生化和应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

An isomeric mixture of homogeranyl/homoneryl triazole bisphosphonates (VSW1198) has previously been shown to be a potent inhibitor of geranylgeranyl diphosphate (GGDP) synthase (GGDPS) and of therapeutic interest for the treatment of multiple myeloma. We have developed and validated a selective and sensitive liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method for the simultaneous quantitation of both the E- and Z-isomers of VSW1198 in cell culture media, mouse plasma and tissues. VSW1198 and internal standard are extracted from the bio-matrices by solid-phase extraction, followed by derivatization using trimethylsilyldiazomethane. The chromatographic separation of analytes was achieved on a Phenomenex Gemini NX column (150mm*2.0mm, 5μ) with gradient elution using 0.1 % acetic acid and methanol/acetonitrile (1:1) as the mobile phase at a flow rate of 0.2 mL/min. Derivatized analytes were ionized with an electrospray ionization source in positive multiple reaction monitoring (MRM) mode and quantitated using MS/MS. The MS/MS response was linear over the concentration range from 0.38–1500 and 0.13 to 500 ng/mL for the E- and Z-isomers, respectively. The within- and between-day precision (relative standard deviation, % RSD) and accuracy were within the acceptable limits per FDA guidelines. The validated method was used for quantitative determination of the compounds in preclinical studies focused on the development of VSW1198 as a novel anti-cancer agent.
机译:先前已显示高香叶基/壬基三唑双膦酸酯(VSW1198)的异构体混合物是香叶基香叶基二磷酸(GGDP)合酶(GGDPS)的有效抑制剂,对多发性骨髓瘤的治疗具有治疗意义。我们已经开发并验证了选择性灵敏液相色谱与串联质谱法(LC-MS / MS)相结合的方法,用于同时定量测定细胞培养基,小鼠血浆和组织中VSW1198的E和Z异构体。通过固相萃取从生物基质中萃取VSW1198和内标,然后使用三甲基甲硅烷基重氮甲烷进行衍生化。在Phenomenex Gemini NX色谱柱(150mm * 2.0mm,5μ)上使用0.1%乙酸和甲醇/乙腈(1:1)作为流动相,以0.2 mL / mL的流速进行梯度洗脱,实现了分析物的色谱分离分钟衍生的分析物在正多反应监测(MRM)模式下用电喷雾电离源电离,并使用MS / MS进行定量。对于E和Z异构体,在0.38–1500和0.13至500 ng / mL的浓度范围内,MS / MS响应呈线性关系。日内和日间精度(相对标准偏差,%RSD)和精度均在FDA准则允许的范围内。经过验证的方法用于临床前研究中化合物的定量测定,该研究的重点是开发作为新型抗癌药VSW1198的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号